Micromet Gets $14M Upfront From Amgen For BiTE Technology
This article was originally published in The Pink Sheet Daily
The world's largest biotech is investing in the research of BiTE antibodies against three undisclosed solid tumor targets.
You may also be interested in...
Along with three biotech acquisitions, the week in deal-making also saw the licensing of a new hepatitis C candidate with a different mechanism of action, further consolidation in the animal health field, and the end of Ipsen and Santhera’s collaboration on Alzheimer’s drug fipamezole.
With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.